Listing 1 - 10 of 29 | << page >> |
Sort by
|
Choose an application
Angiogenesis Inhibitors --- Angiogenesis Inhibitors --- immunology. --- metabolism.
Choose an application
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews ha
Choose an application
Les VDA constituent une nouvelle classe d'agents anticancéreux, ciblant les vaisseaux sanguins préexistants au sein de la tumeur. Ils induisent une diminution du flux sanguin tumoral et une nécrose au centre de la tumeur laissant une bordure de cellule viable à la périphérie, ce qui provoque une repousse de la tumeur. Ce phénomène constitue une limite dans l'utilisation des VDA en monothérapie. Des nombreuses associations aux VDA permettant d'augmenter leur efficacité sont en cours d'évaluations dans les essais cliniques et les résultats sont très encourageants. A ce titre, nous pouvons évoquer l'association de VDA avec les agents de la chimiothérapie, avec la radiothérapie, ou encore avec les agents anti-angiogéniques. Parmi les cancers les plus étudiés, on peut citer le cancer du poumon non à petites cellules (SNCLC), le Cancer anaplasique de la thyroïde, le cancer de la prostate ou le cancer rénal. Nous détaillerons donc, dans ce mémoire, les différentes combinaisons citées ci-dessus. Vascular Disrupting agents or « VDa » constitute a new class of anticancer agent, targeting existing blood vessels within the tumor. They induce tumor blood flow shutdown and necrosis in the center of the tumor and leave a rim of viable cells in the periphery, which causes a regrowth of the tumor. This phenomenon is a limitation in the use of VDA as monotherapy. Many clinical trials associating VDA to chemo or radio-therapy, or anti-angiogenic are ongoing with promising results. The most studied cancers include non-small cell lung cancer (NSCLC), anaplastic thyroid cancer, prostate cancer or renal cancer. In this work, combinations of those above listed associations and cancer types are being described.
Angiogenesis Inhibitors --- Blood Vessels --- Neoplasms --- Antineoplastic Agents
Choose an application
Angiogenesis plays rate limiting roles in tumor growth and invasion. Angiogenesis inhibition has been proposed as a general strategy to fight against cancers. This book covers different therapeutic targets for angiogenesis interventions with emphasis on clinical development of antiangiogenic drugs that target antiangiogenic cascade in different forms of cancers like breast cancer, multiple myeloma, renal carcinoma, gastrointestinal, prostate and lung cancer.
Neovascularization inhibitors. --- Cancer --- Angiogenesis Inhibitors. --- Treatment.
Choose an application
Neovascularization inhibitors. --- Neovascularization. --- Blood-vessels --- Angiogenesis inhibitors --- Tumor angiogenesis inhibitors --- Antineoplastic agents --- Growth
Choose an application
Choose an application
Neovascularization inhibitors --- Angiogenesis Inhibitors --- Neoplasms --- therapeutic use --- drug therapy
Choose an application
Angiogenesis is an extension process of the cardiovascular network within human body. It is usually triggered by the demand of oxygen and nutrients from the fast growing tissue and uncontrollably dividing cells, as seen during wound healing and tumor progression. This book focuses on tumor angiogenesis and includes 8 chapters written by highly experienced scholars from five different countries. It is the goal of this book to provide readers with an update on the molecular and cellular mechanisms of this biological process and hopefully to point out some new research directions for future therapeutic adventure.
Tumors --- Neovascularization inhibitors. --- Blood-vessels. --- Cancer --- Angiogenesis inhibitors --- Tumor angiogenesis inhibitors --- Antineoplastic agents --- Blood-vessels --- Cardiovascular medicine
Choose an application
Neovascularization inhibitors. --- Tumors --- Neovascularization. --- Blood-vessels. --- Blood-vessels --- Cancer --- Angiogenesis inhibitors --- Tumor angiogenesis inhibitors --- Antineoplastic agents --- Growth
Choose an application
Listing 1 - 10 of 29 | << page >> |
Sort by
|